Speakers

Alfica Sehgal

Senior Vice President, Head of Discovery and Translation

CAMP4 Therapeutics

Allyson Berent

Chief Scientific Officer

Foundation for Angelman Syndrome Therapeutics (FAST)

Alysson Murotri

Professor

UC David Stem Cell Program

Andrew Young

Director

Sangamo

Brian Harvey

Scientist

Biogen

Bruce Bloom

Chief Collaboration Officer

Healx

Christopher U Missling

President & Chief Executive Officer

Anavex Life Science Corp

Daniel Lavery

Chief Scientific Officer

Loulou Foundation

Elizabeth Berry-Kravis

Professor

Rush University Medical Center

Erin Rosenbaugh

Scientific Project Manager

FNIH

Gopi Shanker

Chief Scientific Officer

Tevard Biosciences

Heather Lau

Executive Director Global Clinical Development

Ultragenyx

Holly Kordasiewicz

Vice President Neurology Research

Ionis Pharmaceuticals

Jana Von Hehn

Chief Scientific Officer

Rett Syndrome Research Trust

Jennifer Panagoulias

Regulatory Affairs and Compliance Professional

Angelman Syndrome Biomarker and Outcome Measure Consortium

Leonard Abbeduto

Director & Professor

MIND Institute, Psychiatry and Behavioural Sciences, University of California Davis

Luke Rosen

Founder

KIF1A.ORG

Lynn-Allison Durham

Founder & Chief Executive Officer

STALICLA

Massimillio Bianchi

Founder, President & Chief Executive Officer

Ulysses

Onno Faber

Chief Executive Officer

Rarebase

Paulina Rychenkova

Founder

CureSHANK

Rachael Hawtin

Executive Director, Clinical Biomarker Development & Strategy

Ultragenyx

Robert Ring

Chief Scientific Officer

Kaerus Bioscience

Sam Benezra

Scientist

Biogen

Samir Koirala

Director

Biogen

Sarah Glass

Chief Operating Officer

n-Lorem Foundation

Susanne Clinch

Principal Patient Centered Outcomes Research Scientist

Roche

Tracy Cole

Senior Director, Research and Development

n-Lorem

Wesley Horton

Senior Project Manager

FNIH

Xavier Liogier

Chief of Translational Science

Loulou Foundation

Yael Weiss

Chief Executive Officer

Mahzi Therapeutics